Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 4/1999

01-02-1999 | ORIGINAL ARTICLE

A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients

Authors: Brigitte Tranchand, Carole Amsellem, Etienne Chatelut, Gilles Freyer, Athanassios Iliadis, Blandine Ligneau, Véronique Trillet-Lenoir, Pierre Canal, Isabelle Lochon, Claude Joseph Ardiet

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/1999

Login to get access
Metadata
Title
A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients
Authors
Brigitte Tranchand
Carole Amsellem
Etienne Chatelut
Gilles Freyer
Athanassios Iliadis
Blandine Ligneau
Véronique Trillet-Lenoir
Pierre Canal
Isabelle Lochon
Claude Joseph Ardiet
Publication date
01-02-1999
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/1999
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s002800050901

Other articles of this Issue 4/1999

Cancer Chemotherapy and Pharmacology 4/1999 Go to the issue

ORIGINAL ARTICLE

Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma

SHORT COMMUNICATION

Expression of GADD153 in tumor cells and stromal cells from xenografted tumors in nude mice treated with cisplatin: correlations with cisplatin-DNA adducts

ORIGINAL ARTICLE

Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients

ORIGINAL ARTICLE

Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines

ORIGINAL ARTICLE

Aerosol delivery of liposomal all-trans -retinoic acid to the lungs

ORIGINAL ARTICLE

Mechanism of cytotoxicity of N -[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits